|
End-of-day quote
Shanghai S.E.
06/03/2026
|
5-day change
|
1st Jan Change
|
|
55.56 CNY
|
+3.43%
|
 |
-1.77%
|
-6.73%
|
|
02/09/25 |
TGFB Inhibitor Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
|
AQ
| |
20/08/25 |
Jiangsu Hengrui Medicine : Hengrui Pharma Has Announced its Record-breaking First-half 2025 Results
|
PU
| |
01/08/24 |
Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs
|
AQ
| |
10/07/24 |
Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type a FDA Meeting
|
AQ
| |
14/05/24 |
Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
|
AQ
| |
08/02/24 |
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China
|
AQ
| |
05/12/23 |
Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 | Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.
|
AQ
| |
22/11/23 |
HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
|
AQ
| |
09/11/23 |
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
|
AQ
| |
27/09/23 |
Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)
|
AQ
| |
22/08/23 |
Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis in China
|
AQ
| |
10/04/23 |
Jiangsu Hengrui Medicine : Hengrui Pharma Announces Positive Data of Two ADC Programs at the AACR Annual Meeting 2023
|
PU
| |
14/03/23 |
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type
|
AQ
| |
18/08/20 |
Thermo Fisher Scientific : Signs Companion Diagnostic Agreement with Hengrui Therapeutics Inc
|
AQ
| |
17/06/19 |
Jiangsu Hengrui Medicine : Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine Announce Partnership to Develop and Commercialize VT-1161 for Recurrent Vulvovaginal Candidiasis and Other Fungal Conditions
|
BU
| |
05/01/18 |
Jiangsu Hengrui Medicine : and Arcutis Announce a Development and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302
|
BU
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
